FDA Recalls Subpotent Nandrolone Decanoate Compounding Ingredient
Fagron, Inc initiated a nationwide recall of Nandrolone Decanoate compounding ingredient due to subpotency. The affected lot may contain below-strength concentrations of the active pharmaceutical ingredient.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III voluntary recall with no reported illnesses or injuries. Subpotency is a quality defect affecting drug efficacy but not creating immediate safety risk. Per the severity rubric, Class III recalls are typically scored 1 or 2, and voluntary quality defects without reported harm score as Moderate.
Plain-English summary
Fagron, Inc initiated a voluntary recall of Nandrolone Decanoate, USP (National Drug Code 0395-8212-43), supplied as 1-kilogram plastic containers for prescription compounding use. The affected lot is #18L12-U02-050019, which expired October 31, 2022. The recall was initiated on March 4, 2022, and reported to the FDA on May 18, 2022.
The product was found to be subpotent, meaning the concentration of the active pharmaceutical ingredient is below the labeled strength. This is a quality defect that could affect the efficacy of compounded preparations made from this material.
The affected lot was distributed nationwide within the United States through the distributor Humco, located at 7400 Alumax Road, Texarkana, Texas 75501. The recall status was terminated on July 14, 2024.
Healthcare providers, compounding facilities, and those who may possess this lot should consult with Fagron, Inc or the FDA for guidance regarding inventory management.
The recalled product
- Product
- Nandrolone Decanoate, USP, 1 kg per plastic container, Rx Only, For Prescription Compounding, Distributed by: Humco, 7400 Alumax Road, Texarkana, TX 75501. NDC 0395-8212-43
- Manufacturer
- Fagron, Inc
- Category
- Drug
- Hazard
- subpotency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 18L12-U02-050019
- Exp. Date 10/31/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27